André Volland (Andre Volland)

Publication Activity (10 Years)

Years Active: 2021-2022
Publications (10 Years): 4

Top Topics

Respiratory Syndrome Coronavirus

High Throughput

Top Venues

Emerging microbes & infections

Science translational medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Michaela Lackner, Annika Rössler, André Volland, Marlena Nastassja Stadtmüller, Brigitte Müllauer, Zoltan Banki, Johannes Ströhle, Angela Luttick, Jennifer Fenner, Bettina Sarg, Leopold Kremser, Paul Tone, Heribert Stoiber, Dorothee von Laer, Thorsten Wolff, Carsten Schwarz, Markus Nagl
N-chlorotaurine is highly active against respiratory viruses including SARS-CoV-2 (COVID-19) in vitro . Emerging microbes & infections 11 (1) (2022)
Emmanuel Heilmann, Francesco Costacurta, Seyed Arad Moghadasi, Chengjin Ye, Matteo Pavan, Davide Bassani, André Volland, Claudia Ascher, Alexander Kurt Hermann Weiss, David Bante, Reuben Stewart Harris, Stefano Moro, Bernhard Rupp, Luis Martinez-Sobrido, Dorothee von Laer
SARS-CoV-2 3CL pro mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376. Science translational medicine (2022)
Gabriel E Wagner, Massimo G Totaro, André Volland, Michaela Lipp, Sabine Saiger, Sabine Lichtenegger, Patrick Forstner, Dorothee von Laer, Gustav Oberdorfer, Ivo Steinmetz
A Novel High-Throughput Nanopore-Sequencing-Based Strategy for Rapid and Automated S-Protein Typing of SARS-CoV-2 Variants. Viruses 13 (12) (2021)
André Volland, Michael Lohmüller, Emmanuel Heilmann, Janine Kimpel, Sebastian Herzog, Dorothee von Laer
Heparan sulfate proteoglycans serve as alternative receptors for low affinity LCMV variants. PLoS pathogens 17 (10) (2021)